Targeted Genetics Corporation announced today issuance of U.S. patent #6,887,463, entitled, "Methods and Compositions for Gene Therapy for the Treatment of Defects in Lipoprotein Metabolism."
MicroVention announced today that the U.S. Patent and Trademark Office has awarded the company U.S. Patent No. 6,878,384 for its proprietary environmentally-responsive or "smart" hydrogel called
The University of Rochester has filed a patent on several ideas to help prevent early labor and the premature delivery of low-birth-weight babies. The discovery is an incremental step in an area
The University of Rochester has filed a patent on several ideas to help prevent early labor and the premature delivery of low-birth-weight babies. The discovery is an incremental step in an area
Primagen Holding BV has announced that the U.S. Patent and Trademark Office has granted a patent for its Mitox mitochondrial DNA quantification technology as biomarkers for efficacy and adverse events
Neuren Pharmaceuticals has announced that its patent application entitled "GPE Analogs and Peptidomimetics" (PCT/US02/16361) has been issued in the United States (US Patent No: 7,041,314) on 9 May
Shire plc has announced that its subsidiary Shire Laboratories has filed a lawsuit in the U.S. District Court for the District of New Jersey against Corepharma LLC for infringement of some of Shire Labor
SuperGen has announced the issuance of U.S. Patent No. 7,037,900 B2 entitled, "Composition and Method for Treating Graft-versus-Host Disease." The patent contains 39 claims relating to the com
Cutera today announced that it has settled all patent infringement lawsuits with Palomar Medical Technologies, Inc. As part of this transaction, Cutera and Palomar have agreed to refrain from a
Nventa Biopharmaceuticals Corporation announced that the European Patent Office has granted Patent Number EP 941,315 to Nventa. The patent covers compositions of fusion proteins comprised of
Zyomyx has built a United States and international patent estate that includes over 90 patents and pending patent applications. Together with rights to patents licensed by others, Zyomyx owns or has exclusive rights to more than 120 United States and international patents and patent applications. The five new patents include: U.S. Patent 6,730,516, entitled "Microfluidic Devices and Methods"; U.S. Patent 6,720,165, entitled "Methods for Making Antibody Fragments and Compositions Resulting Therefrom"; U.S. Patent 6,720,157, entitled "Chips Having Elevated Sample Surfaces"; U.S. Patent 6,186,154, entitled, "Screening of Phage Displayed Peptides without Clearing of Cell Culture"; and U.S. Patent 6,682,942, entitled, "Microdevices for Screening Biomolecules".
"The recognition by the United States Patent and Trademark Office in granting these five patents, as well as the numerous other U.S. patents that have been granted or allowed, is exciting for Zyomyx as we continue our pioneering efforts in the commercialization of protein biochip technologies in anticipation of our customers' current and future research needs," said Robert Monaghan, Zyomyx' President and Chief Executive Officer.
The Company has a strong intellectual property position in protein biochips and in other related micro-scale protein analytical methodologies. Since its founding in 1998, Zyomyx has pursued an aggressive intellectual property strategy aimed at creating substantial barriers for other companies in the protein biochip business and also at providing appropriate freedom to operate in the development and application of its core proteomics and nanofluidic technologies.
http://www.zyomyx.com/